Small‐molecule drugs targeting the KRAS‐G12C have been approved for non‐small cell lung cancer, whereas drugs targeting the KRAS‐G12D mutant are currently under clinical investigation.[25, 26] However, due to the lack of distinctive structural feature in the KRAS‐G12V protein, developing small molecule drugs specifically targeting KRAS‐G12V remains a challenge. This evidence concerns the gene KRAS and lung cancer.